You are here: Industry Insights > Genentech

News List

Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children drugs
June 29, 2021
Genentech announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults and pediatric patients
Pieris and Genentech sign $1.4bn respiratory and ophthalmology deal pharmaceutical-technology
May 27, 2021
Pieris Pharmaceuticals and Roche Group subsidiary Genentech have signed a multi-programme research partnership and licence agreement worth approximately $1.42bn to discover, develop and market respiratory and ophthalmology therapies.
UK cancer centre to offer breast cancer treatment at home pharmatimes
April 29, 2021
The Christie NHS Foundation Trust has become the first cancer centre in the UK to offer the treatment Phesgo, developed by Roche’s Genentech division, for breast cancer at home.
New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis americanpharmaceuticalreview
April 21, 2021
Genentech, a member of the Roche Group, announced new Ocrevus® (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as ...
Natera, Genentech Initiate Phase III Trial Using Signatera americanpharmaceuticalreview
March 17, 2021
Natera announced the first patient has been screened in a new phase III clinical trial that uses its tumor-informed, personalized molecular residual disease (MRD) test, Signatera, as a companion diagnostic to identify muscle-invasive urothelial ...
Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers expresspharma
December 03, 2020
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations.
Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukaemia expresspharma
October 19, 2020
Genentech, a member of the Roche Group, announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment ...
Vaccibody signs agreement with Genentech for individualised neoantigen cancer vaccines pharmaceutical-technology
October 10, 2020
Biopharmaceutical company Vaccibody has signed an exclusive worldwide license and collaboration agreement with Genentech for the development and commercialisation of DNA-based individualised neoantigen cancer vaccines.
French authority orders €444m fine on Novartis, Roche over Lucentis pharmaceutical-technology
September 24, 2020
The French competition authority has imposed a total fine of €444m on Novartis, Roche and Genentech for allegedly following abusive practices to push more sales of eye disease drug Lucentis than a cheaper drug.
Scenic Biotech, Genentech Enter Genetic Modifier Alliance contractpharma
September 22, 2020
Strategic collaboration will leverage Scenic Biotech’s disease modifying Cell-Seq platform in deal that could exceed $375M.

Previous page 1 2 3 4 5 6 7 8 Next page